Navigation Links
Gentiva Reports First Quarter 2009 Results
Date:4/30/2009

ntribution and EBITDA for the first quarter of 2009 and 2008 included special charges of $0.9 million and $0.3 million, respectively. The special charges, which included restructuring and integration costs and costs and professional fees associated with merger and acquisition activities, were reflected as follows for segment reporting (dollars in millions): 1st Quarter ----------- 2009 2008 ---- ---- Home Health $0.1 $0.1 Corporate expenses 0.8 0.2 ---- ---- Total $0.9 $0.3 ==== ==== (4) Operating contribution for CareCentrix, in which the Company sold a majority ownership interest on September 25, 2008, was comprised of the following (dollars in thousands): 1st Quarter ----------- 2009 2008 ---- ---- Gross profit $- $14,290 Selling, general and administrative expenses - (8,077) Add: depreciation - 113 -- ------ Operating contribution $- $6,326
'/>"/>
SOURCE Gentiva Health Services, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. Gentiva(R) Health Services Schedules First Quarter Earnings Call and Web Cast for Thursday, April 30, 2009
2. Gentiva(R) Health Services to Present at Upcoming Investor Conferences
3. Gentiva(R) Health Services Sells Selected Pediatric Home Health Care Branches
4. Gentiva(R) Health Services Schedules Fourth Quarter and Fiscal 2008 Earnings Call and Web Cast for Wednesday, February 18, 2009
5. Gentiva(R) Health Services to Present January 13 at J.P. Morgan Healthcare Conference in San Francisco
6. Gentiva Health Services Confirms Management Succession
7. Gentiva(R) Health Services to Present at November Investment Conferences Hosted by Oppenheimer, Credit Suisse and Stephens
8. Gentiva Reports Third Quarter Revenue and Profit Growth
9. Gentiva Safe Strides(R) Home Balance Therapy Program is Reducing Risk of Dangerous Falls and Relieving Pain for Thousands of Older Americans
10. Gentiva(R) Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday, July 31, 2008
11. Gentiva(R) Health Services to Present June 24 at Jefferies 2nd Annual Healthcare Conference in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... holidays are rapidly approaching and what would be the perfect gift ... cells, of course! Celebrity Beauty Engineer® and Licensed Esthetician Mary Schook ... to look and feel their best! , ... (PRWEB) ... kind of gift does a person get that special woman who ...
(Date:12/15/2009)... have successfully developed a new electrophoretic method for ... blood. The technique, using SARCOSYL-PAGE, has specifically ... the performance characteristics of SDS-PAGE for detecting other ... a grant from the World Anti-Doping Agency (WADA), ... Testing and Analysis published by Wiley-Blackwell. , ...
(Date:12/15/2009)... State Authority, Ban on Annual Benefit Limits, & ... Consumer Watchdog condemned the removal of ... and the public option from the U.S. Senate ... the Senate must still make three essential fixes ... the entire health care system to the insurance ...
(Date:12/15/2009)... Palo Alto Networks(TM), the network security ... its PA-4000 Series next-generation firewalls for accurate threat ... visibility and control over applications such as peer-to-peer ... national university with eight facilities on five campuses. ... a number of academic schools and institutions throughout ...
(Date:12/15/2009)... Lady of Lourdes Health Care Services Inc., the parent ... pay the United States $7.95 million to resolve allegations ... today. The two hospitals are Our Lady of Lourdes ... Center of Burlington County (LMC) in Willingboro, N.J. ... by a whistleblower, Tony Kite, in 2005. The lawsuit ...
Breaking Medicine News(10 mins):Health News:New Online Beauty Store Suggests Stem Cells for the Woman Who Has Everything 2Health News:Researchers discover novel method for detecting MIRCERA 2Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 2Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 3Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 4Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 5Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations 2
... neurological reward responses , MONDAY, Dec. 3 (HealthDay News) ... brain activity patterns than those who,ve never had the ... at the University of Pittsburgh School of Medicine used ... women who,d recovered from anorexia -- defined as maintaining ...
... are clumps of fiber-like misfolded proteins which many ... , While effective treatment remains an elusive goal, ... chemists suggests a possible new approach. , ... students managed to capture and characterize a crucial ...
... Crawford brings more than 30 years of experience in Public Safety ... ... ESi(R), the global leader in,crisis information management technology, today announced ... Northeast.,Crawford is based in Boston, where he is responsible for ESi ...
... conference to discuss new Medicaid generic prescription drug,reimbursement rule ... use his,power to make sure the legislative fix is ... to be fully implemented in early,2008, will grossly underpay ... Brad Hall, Executive Director of the Kentucky Pharmacists ...
... 3 inVentiv Health, Inc.,(Nasdaq: VTIV ) today ... be held Tuesday, December 11th, 2007 in New York ... 9:00 a.m. as announced earlier, and,will conclude at noon, ... business overview, presentations by the,leaders of each of the ...
... ReBuilder Medical,Technologies, Inc. (Pink Sheets: RBRM), developers ... peripheral neuropathy, Molluscum,Contagiosum, and MRSA announces record profits ... ), "Corporate profits increased by 100% over ... disclosure will be released on our annual report,in ...
Other Medicine News:Health News:Brain Activity Points to Origins of Anorexia 2Health News:UIC chemists characterize Alzheimer's neurotoxin structure 2Health News:ESi Announces Strategic New Hire in Boston 2Health News:Kentucky Pharmacists Event Urging Senate Minority Leader McConnell to Fix Flawed Medicaid Drug Reimbursement Rule 2Health News:inVentiv Health Provides Updated Information on December 11th Investor Day 2Health News:inVentiv Health Provides Updated Information on December 11th Investor Day 3Health News:ReBuilder Medical Technologies, Inc. Reports Doubled Profits for October 2
(Date:12/15/2009)... Services, Inc. (NYSE: WST ) today announced ... the first-quarter 2010 cash dividend of $0.16 per share. ... to shareholders of record on January 20, 2010. ... global manufacturer of components and systems for injectable drug ... and disposable components used in syringe, IV and blood ...
(Date:12/15/2009)... Del., Dec. 15 The U.S. Food and ... (EMDAC) today voted 12 yes, 4 no, and 1 ... the observed risks to support the use of CRESTOR® ... Men greater than or equal to 50 years, ... Fasting LDL < 130 mg/dL; hsCRP greater than ...
(Date:12/15/2009)... SRI International, an independent nonprofit research and development ... 7,592,021 for a new bioadhesive drug delivery system ... human body,s mucous membranes. This needle-free option uses ... much longer release time compared to alternatives such ... an effective means to introduce drugs across the ...
Breaking Medicine Technology:Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 3Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 4Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 5SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 2SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 3SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 4SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 5Are intravenous treatments safe 3F New research raises doubts 55731 1Are intravenous treatments safe 3F New research raises doubts 55731 2Open source DNA 55727 1New developments in reproductive medicine 9741 1New developments in reproductive medicine 9741 2
... Biotechnologies,announced today the results of Phase I/II and ... sarcoma and osteosarcoma, as,presented by Dr. Sant P. ... held in London UK on November 13-15, 2008. ... period up to 9 months. Analysis of,safety and ...
... PHILADELPHIA, Nov. 20 GlaxoSmithKline (NYSE: GSK ... and Drug Administration (FDA) granted accelerated approval for ... patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) ... immunoglobulins or splenectomy. The approval is a significant ...
Other Medicine Technology:Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8
Four 62 mirrors give a 360 view of the anterior chamber angle with only a slight lens rotation. Posterior pole can be viewed through center of lens....
Two opposing 62 mirrors provide a complete view of the anterior chamber angle with only a 180 lens rotation. Methylcellulose and no methylcellulose designs available....
Lacrimal cannula blunt tip with 0.3 mm side port, straight....
McIntyre lacrimal cannula, dual 0.3 mm side ports, straight....
Medicine Products: